3 Result: Inventiva
Inventiva: Promising Lanifibranor Trial Data; Bullish View Towards 89bio, BRP, CompoSecure
June 13th, 2023
Inventiva S.A. (Nasdaq: IVA), a pharmaceutical company, has announced encouraging results from a Phase II clinical trial evaluating lanifibranor in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D). Th. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Upgraded Rating for The Gap, First Commonwealth Financial, Wendy's, MaxLinear, and Inventiva
May 20th, 2023
The Gap, Inc. (NYSE: GPS) received an upgrade from Sell to Neutral by Citigroup, a notable financial institution. This upgrade suggests a shift in sentiment towards the company. On Friday, $GPS closed at $7.78, experiencing a decline of $0.33 (-4.07%. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Countdown: Lockheed Martin, Stryker, and PACCAR Gear Up
January 26th, 2025Earnings Spotlight: SoFi Technologies, Sanmina, and Nucor Set to Report
January 26th, 2025Global Flag Football League Plans To Host Pro Flag Football Tournament in Las Vegas
January 23rd, 2025Earnings On Deck: Netflix, United Airlines, and Agilysys Gear Up
January 19th, 2025
Member Login